CHARMACY PHAR (02289) released its interim results, with a net profit attributable to the parent company of 22.556 million yuan, an increase of 3.76% year-on-year.

CHARMACY PHAR (02289) has announced its interim results for the six months ending June 30, 2026. The group achieved operating revenue of 2.448 billion yuan, an increase of 13.6% year-on-year; the net profit attributable to shareholders of the parent company was 22.556 million yuan, up 3.76% year-on-year; basic and diluted earnings per share were 0.2088 yuan. The announcement stated that the increase in operating revenue was mainly due to the continued robust growth of domestic retail terminal drug demand, the rising public health awareness driving the ongoing expansion of retail pharmacy channels, and an overall improvement in the market environment. The group has deepened brand cooperation: it continues to implement the market strategy of "deepening in Guangdong and radiating to surrounding areas," further enhancing its recognition among brand manufacturers, acquiring more high-quality product distribution rights and project cooperation opportunities, and continually strengthening its supply chain advantages. This includes progressively increasing product supply fulfillment rates, optimizing the supply chain service system, and achieving widely recognized, efficient, and stable supply chain services, which have enhanced customer satisfaction and brand influence, laying a solid foundation for the stable growth of the groups core business.